Leading European Biologics CDMO Mabion, Releases First Batch Of Novalgen's Next-Generation T-Cell Engager, NVG-222 For ...
In a significant move to accelerate the global fight against blood cancers and hard-totreat solid tumours, renowned end-to-end biologics CDMO Mabion have entered into a strategic development and manufacturing partnership with London based NovalGen an …